Abstract
Tedizolid is a novel, expanded-spectrum oxazolidinone with potent activity against a wide range of Gram-positive pathogens. A total of 425 isolates of Gram-positive bacteria were obtained consecutively from patients with acute bacterial skin and skin structure infections (ABSSSIs) or pneumonia. These isolates included methicillin-susceptible Staphylococcus aureus (MSSA) ( n = 100), methicillin-resistant Staphylococcus aureus (MRSA) ( n = 100), Streptococcus pyogenes ( n = 50), Streptococcus agalactiae ( n = 50), Streptococcus anginosus group ( n = 75), Enterococcus faecalis ( n = 50), and vancomycin-resistant enterococci (VRE) ( Enterococcus faecium ) ( n = 50). The MICs of tedizolid and linezolid were determined by the agar dilution method. Tedizolid exhibited better in vitro activities than linezolid against MSSA (MIC 90 s, 0.5 versus 2 μg/ml), MRSA (MIC 90 s, 0.5 versus 2 μg/ml), S. pyogenes (MIC 90 s, 0.5 versus 2 μg/ml), S. agalactiae (MIC 90 s, 0.5 versus 2 μg/ml), Streptococcus anginosus group (MIC 90 s, 0.5 versus 2 μg/ml), E. faecalis (MIC 90 s, 0.5 versus 2 μg/ml), and VRE (MIC 90 s, 0.5 versus 2 μg/ml). The tedizolid MICs against E. faecalis ( n = 3) and VRE ( n = 2) intermediate to linezolid (MICs, 4 μg/ml) were 1 μg/ml and 0.5 μg/ml, respectively. The tedizolid MIC 90 s against S . anginosus , S. constellatus , and S. intermedius were 0.5, 1, and 0.5 μg/ml, respectively, and the rates of susceptibility based on the U.S. FDA MIC interpretive breakpoints to the isolates were 16%, 28%, and 72%, respectively. Tedizolid exhibited 2- to 4-fold better in vitro activities than linezolid against a variety of Gram-positive cocci associated with ABSSSIs and pneumonia. The lower susceptibilities of tedizolid against isolates of S. anginosus and S. constellatus than against those of S. intermedius in Taiwan were noted.

This publication has 17 references indexed in Scilit: